Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
0.9% bacteriostatic saline is a sterile solution of sodium chloride in water for injection, containing 0.9% (9 mg/mL) of benzyl alcohol as a bacteriostatic preservative. While traditionally used as a sterile vehicle for diluting or dissolving drugs for injection, it is being investigated by the University of California, San Francisco (UCSF) for its off-label use as a local anesthetic in minor eyelid procedures. The anesthetic effect is attributed to the benzyl alcohol component, which is an aromatic alcohol that provides rapid, short-acting local anesthesia. A Phase 4 clinical trial (NCT05294640) is evaluating its efficacy and patient comfort compared to lidocaine with epinephrine for procedures involving eyelid tumors, abscesses, and other lesions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 0.9% bacteriostatic saline.